These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12394536)

  • 1. Electroconvulsive therapy in a patient receiving rivastigmine.
    Zink M; Sartorius A; Lederbogen F; Henn FA
    J ECT; 2002 Sep; 18(3):162-4. PubMed ID: 12394536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine: a review.
    Sim A
    Hosp Med; 1999 Oct; 60(10):731-5. PubMed ID: 10656066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief review: rivastigmine, a second cholinesterase inhibitor.
    Patterson C; Hogan DB
    Can J Neurol Sci; 2001 Feb; 28 Suppl 1():S122-3. PubMed ID: 11237306
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 12. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
    Adler G; Brassen S
    Neuropsychobiology; 2001; 43(4):273-6. PubMed ID: 11340368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
    Alagiakrishnan K; Sclater A; Robertson D
    J Am Geriatr Soc; 2003 Sep; 51(9):1326. PubMed ID: 12919253
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivastigmine in Alzheimer disease: efficacy over two years.
    Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
    Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine in the treatment of Alzheimer's disease.
    Deleu D
    Eur Neurol; 2001; 46(2):110. PubMed ID: 11528167
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
    Grossberg GT; Stahelin HB; Messina JC; Anand R; Veach J
    Int J Geriatr Psychiatry; 2000 Mar; 15(3):242-7. PubMed ID: 10713582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.